In yesterday’s Wall Street session, Vir Biotechnology Inc. (NASDAQ:VIR) shares traded at $14.35, up 12.99% from the previous session.
As of this writing, 9 analysts cover Vir Biotechnology Inc. (NASDAQ:VIR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $100.00 and a low of $15.00, we find $24.50. Given the previous closing price of $12.70, this indicates a potential upside of 92.91 percent. VIR stock price is now -41.98% away from the 50-day moving average and -42.37% away from the 200-day moving average. The market capitalization of the company currently stands at $1.70B.
There are 1 analysts who have given it a hold rating, whereas 7 have given it a buy rating. Brokers who have rated the stock have averaged $34.75 as their price target over the next twelve months.
With the price target reduced from $35 to $34, JP Morgan Upgraded its rating from Neutral to Overweight for Vir Biotechnology Inc. (NASDAQ: VIR).
In other news, SATO VICKI L, Director sold 18,000 shares of the company’s stock on Jun 30. The stock was sold for $443,916 at an average price of $24.66. Upon completion of the transaction, the Director now directly owns 1,315,351 shares in the company, valued at $18.88 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 30, 10% Owner SVF Endurance (Cayman) Ltd sold 700 shares of the business’s stock. A total of $17,577 was realized by selling the stock at an average price of $25.11. This leaves the insider owning 16,684,041 shares of the company worth $239.42 million. Insiders disposed of 15,986,200 shares of company stock worth roughly $229.4 million over the past 1 year. A total of 1.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VIR stock. A new stake in Vir Biotechnology Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $24,152,000. SOFINNOVA INVESTMENTS, INC. invested $9,436,000 in shares of VIR during the first quarter. In the first quarter, BRAIDWELL LP acquired a new stake in Vir Biotechnology Inc. valued at approximately $8,668,000. BALYASNY ASSET MANAGEMENT L.P. acquired a new stake in VIR for approximately $5,782,000. JUPITER ASSET MANAGEMENT LTD purchased a new stake in VIR valued at around $5,649,000 in the second quarter.
Friday morning saw Vir Biotechnology Inc. (NASDAQ: VIR) opened at $12.98. During the past 12 months, Vir Biotechnology Inc. has had a low of $12.56 and a high of $31.55. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.90, and a quick ratio of 4.90. The fifty day moving average price for VIR is $24.54 and a two-hundred day moving average price translates $24.87 for the stock.
The latest earnings results from Vir Biotechnology Inc. (NASDAQ: VIR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$1.06, missing analysts’ expectations of -$0.87 by -0.19. This compares to $3.85 EPS in the same period last year. The net profit margin was -32.20% and return on equity was -7.10% for VIR. The company reported revenue of $62.96 million for the quarter, compared to $1.23 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -94.89 percent. For the current quarter, analysts expect VIR to generate $25.89M in revenue.
Vir Biotechnology Inc.(VIR) Company Profile
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
